Proactive Investors - Run By Investors For Investors

Wattle Health Australia eyes Chinese infant formula market

Commencing initial supply of its infant formula to 100 key stores.
Wattle Health Australia eyes Chinese infant formula market
The company listed on the ASX in March 2017

Recently listed Wattle Health Australia (ASX:WHA) has signed an agreement with one of the largest retailers of mother and baby products in China - Aiyingdao Zhuhai Business Chain.

As part of the agreement, Wattle Health will commence initial supply of its infant formula to 100 key stores of Aiyingdao across mainland China.

It is worth noting that Aiyingdao’s network is responsible for 40% of all infant formula sales in China, with over 1000 retail store locations.

The companies are also commencing negotiations to formalise a long-term supply agreement to market infant formula across the entire Aiyingdao network in mainland China.

Based in Melbourne Victoria, Wattle Health is in the business of developing and marketing consumer food products, with an initial focus on dairy products (dried milk and infant formula).

The company listed on the ASX in March 2017 after raising $8 million from an oversubscribed initial public offer.

Interestingly, the company’s shares were last trading at $0.40, double the issue price of $0.20.

Wattle Health uses only Australian manufacturers to manufacture its products.

This is intended to promote and leverage on the brand positively in Australia and in export markets, as there is growing consumer sentiment for Australian made food products.

View full WHA profile View Profile

Wattle Health Australia Ltd Timeline

Related Articles

Callitas CEO James Thompson
July 21 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
parsortix
January 03 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use